

# Update on Avian Influenza

by **Tanya Melillo Fenech MD MSc**  
Principal Medical Officer at Disease Surveillance Unit, Department of Public Health

*The cumulative number of cases is 274 and the deaths are 167. Since the beginning of the year there have been 11 confirmed human cases (in Indonesia, Nigeria and Egypt) of which 9 have died.*

The Food and Agriculture Organization of the United Nations expressed concern about new flare-ups of avian influenza since the beginning of this year in China, Egypt, Indonesia, Japan, Vietnam, Nigeria, South Korea, Thailand, Hungary, UK, Russia and Afghanistan but stressed that the number of outbreaks in the first weeks of 2007 has been significantly lower than the epidemic waves of 2006. The United Nations agency urged countries to remain vigilant and cooperate fully with international organizations.

### Latest on H5N1 virus

Writing in the journal *Nature*, published in January 2007, a group of international scientists revealed the critical clue of how the 1918 influenza virus killed so quickly and efficiently. They showed that the 1918 virus was indeed different from all the other viruses. The team was able to show that the 1918 virus prompted a deadly respiratory infection that echoed historical accounts of how the disease claimed its victims. They showed that infection with the virus prompted an immune response that seemed to derail the body's typical reaction to viral infection and instead unleashes an attack by the immune system on the lungs. As immune cells attack the respiratory system, the lungs fill with fluid and victims, in essence, drown.

The same excessive immune reaction is characteristic of the deadly complications of H5N1 avian influenza, the strain of bird flu present in Asia. However, the H5N1 avian influenza has not yet shown a capacity to spread easily among people.

Knowing that the virus does something during the early stages of

infection to trigger such a devastating immune response may provide biomedical researchers with clues about how to intervene and stop or mitigate the potentially lethal effects of the virus.

### Latest on Antiviruses

#### Amantadine resistance

Published recently in the *New England Journal of Medicine*, a study has shown that there has been a dramatic increase in resistance to amantadine by 70-90% in communities in Asia and North America on patients who have never been previously treated with amantadine.

### Latest update in Research

Recent research done by scientists on mice at St. Jude Children's Research Hospital in Memphis, Tennessee is suggesting that it is possible that some people previously infected with or vaccinated against influenza may have slight protection from H5N1. It is not protection from infection but enough immunity is available to keep the new infection from being deadly.

There are hundreds of 'H' and 'N' designations. The 'H' refers to haemagglutinin, the protein that the flu virus uses to get into cells and the 'N' refers to neuraminidase which is used to get back out of infected cells and spread to others. The H1N1 has been circulating since the 1918 pandemic and a descendant of H1N1 circulates today and is part of the seasonal flu vaccine.

The scientists concluded that having some immunity to N1 might protect people from the worst effects of H5N1. Antibodies to the human version of N1 do cross-react to some extent with the H5N1. ☐

"Rotarix™ provides early protection from rotavirus gastroenteritis, pass it on."



**ROTARIX™** Abbreviated Prescribing Information  
Refer to SPC before prescribing. Rotarix: Live attenuated human rotavirus (R542414 strain) oral vaccine. Usage: Active immunisation of infants from 6 weeks of age against gastroenteritis due to rotavirus infection. Dosage and administration: Two oral doses. First dose can be administered from 6 weeks of age. Minimum interval of 4 weeks between doses. Vaccination course must be completed by 24 weeks of age. Rotarix is for oral use

only. Rotarix should under no circumstances be injected. Contraindications: Hypersensitivity to the active substance or of the excipients. Hypersensitivity after previous administration of rotavirus vaccines. Previous history of intussusception. Subjects with uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception. Infants who have known or suspected immunodeficiency. Asymptomatic HIV infection is not expected to affect the safety or efficacy of Rotarix™. However, in the absence of sufficient data, administration of Rotarix™ to asymptomatic HIV subjects is not recommended. Administration

of Rotarix™ should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contra-indication for immunisation. The administration of Rotarix™ should be postponed in subjects suffering from diarrhoea or vomiting. Precautions: Administer with caution to individuals with gastro-intestinal illness or growth retardation. Administer with caution to individuals with immunodeficient close contacts. Do not inject. Interactions: No interactions with co-administered paediatric vaccines. Pregnancy and Lactation: Not intended for use in adults. Breastfeeding may be continued during the vaccination schedule. Adverse

reactions: Irritability, loss of appetite, diarrhoea, vomiting, flatulence, abdominal pain, regurgitation of food, fever, fatigue. Legal category: POM. Presentations: Pack size of 1 glass container of powder plus 1 oral applicator syringe of solvent to make up 1 dose (1ml) of oral suspension. MA holder: GlaxoSmithKline Biologicals s.a., Route de Termonde 89 1330 Rixensart, Belgium. Further information and full prescribing information: GlaxoSmithKline Malta Tel: 21 238137. Date of preparation: December 2006

**Rotarix™**  
rotavirus vaccine

Early protection from rotavirus gastroenteritis<sup>1,2</sup>